

In the Claims

OK to enter
12.17.04
1.-16. (Canceled)

17. (Currently Amended) A method of inhibiting angiogenesis in a diseased eye of a subject, comprising, administering intraocularly a recombinant adeno-associated virus (rAAV) a-retroviral gene delivery vector which directs the expression of an anti angiogenic factor, such that administration of said vector inhibits neovascularization of the diseased eye.

18. (Previously Presented) The method according to claim 17 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, soluble Tie-2 receptor, or a single chain anti-VEGF antibody.

19. (Previously Presented) The method according to claim 17 wherein said diseased eye is in a subject having diabetic retinopathy, wet AMD or retinopathy of prematurity.

20. – 44. (Canceled)